Arthritis drug linked to rare lupus side effect

[Guest guest]

Arthritis drug linked to rare lupus side effect

NEW YORK, Feb 15 (Reuters Health) - Researchers in Chicago report that

four women with rheumatoid arthritis developed symptoms of the

autoimmune disease systemic lupus erythematosus (SLE) after taking the

drug etanercept (Enbrel).

The patients developed symptoms, including face reddening and body rash,

while taking the drug, but the symptoms disappeared when the drug was

halted, according to a research letter in the February 16th issue of The

Lancet.

Such very rare side effects are not unexpected, said Kris Greco,

spokeswoman for Immunex, the manufacturer of Enbrel.

" In regard to the letter and commentary, what is indicated there is

nothing outside of our label. These reports are part of information that

was provided to the (US Food and Drug Administration) as part of a

comprehensive overview in August. Based on that assessment there were no

new concerns expressed.

" Enbrel has demonstrated an outstanding safety profile supported by 5

years of clinical information, " Greco said. " That's important for the

public and, in particular, patients to understand. "

Enbrel inhibits an immune system protein--called tumor necrosis factor

(TNF)--that is produced in excess in the joints of rheumatoid arthritis

patients. It has been prescribed to an estimated 80,000 patients

worldwide since its launch in the US in 1998 and in Europe in 2000.

Rheumatoid arthritis is an autoimmune disease in which the immune system

attacks the lining of joints, causing pain, stiffness and inflammation.

According to the letter, Dr. Najia Shakoor and colleagues at Rush

Medical College in Chicago, Illinois found the lupus-like symptoms

occurred between 6 weeks and 14 months after the start of treatment with

Enbrel.

Lupus is a disease that can occur in several forms and the condition can

vary widely in severity, manifesting as skin rash and arthritis or

leading to damage to the kidneys, heart, lungs and brain to varying

degrees.

In two of the patients, the SLE diagnosis was deemed " probable " because

of incomplete data.

" Nevertheless, " Shakoor and colleagues write, " in all cases, compelling

evidence for an SLE-like syndrome developed subsequent to etanercept

introduction and resolved rapidly after drug withdrawal. "

The researchers suggest that Enbrel's blocking action of TNF may be to

blame--noting that studies in mice have shown that TNF may have a

" protective role " in SLE. Such drug-induced lupus symptoms are known to

be a rare side effect of another drug on the market that blocks TNF.

However, the authors also note that " identification of drug-induced SLE

among patients with rheumatoid arthritis is difficult owing to extensive

overlap between the two diseases. "

While Shakoor and co-authors point out that they have come across no

other reports of an Enbrel and SLE connection, " these cases suggest that

etanercept might be associated with true drug-induced SLE, " they write.

" Further investigation is necessary to clarify its prevalence and

pathogenesis, " they conclude.

Despite such rare side effects, the authors explain that TNF-blocking

drugs have " been an important advance in treatment " for rheumatoid

arthritis.

Such drugs are " a powerful addition to our therapeutic armamentarium "

and are " generally well tolerated " by patients, they add.

SOURCE: The Lancet 2002;359:579-580.